At Impactus ESG, we are proud to partner with Curity Pharma in advancing the future of medical cannabis — a sector reshaping the landscape of modern healthcare.
As highlighted by Manos Chatiras, President and CEO of Curity Pharma, in a recent interview with Pharma Leaders (featured in ΤΟ ΒΗΜΑ), “Medical cannabis is no longer a last resort — it’s a path forward for patients where conventional treatments fall short.”
Together, we are committed to supporting the development of cannabis-based therapies that prioritize patient safety, quality, and personalized care.
From chronic pain and epilepsy to mental health and neurodegenerative diseases, the therapeutic impact of medical cannabis is rapidly gaining momentum.
At Impactus ESG, we believe that true innovation in healthcare must also be sustainable, responsible, and centered on improving lives. We are honored to contribute to a future where medical cannabis stands as a pillar of progressive, patient-focused medicine.
